Does Pre-Therapy PSA Influence 177Lu-PSMA-617 Treatment Outcomes?

被引：0
|
作者：
Fermawi, S. [1 ]
Buehner, T. [1 ]
Kalarn, S. [2 ]
Sabottke, C. [2 ]
Recio-Boiles, A. [3 ]
Savir-Baruch, B. [1 ]
机构：
[1] Univ Arizona, Div Nucl, Dept Med Imaging, Coll Med Tucson, Tucson, AZ USA
[2] Univ Arizona, Coll Med Tucson, Dept Med Imaging, Tucson, AZ USA
[3] Univ Arizona, Coll Med Tucson, Dept Med Hematol & Med Oncol, Tucson, AZ USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-767
引用
收藏
页码：S363 / S363
页数：1
相关论文
共 50 条
  • [21] Treatment response according to PSA changes in patients undergo more than one cycle of 177Lu-PSMA-617 therapy.
    Wegen, Simone
    Eppard, Elisabeth
    Kuerpig, Stefan
    Yordanova, Anna
    Hauser, Stefan
    Essler, Markus
    Ahmadzadehfar, Hojjat
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [22] 177LU-PSMA-617 PRODUCTION AND QUALITY CONTROL AT THE RAH
    Girvin, Mark
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 14 - 14
  • [23] 177Lu-PSMA-617 for metastatic prostate cancer in India
    Ghose, Aruni
    Banerjee, Soirindhri
    Choudhury, Partha S.
    Maniam, Akash
    Gupta, Manoj
    Banna, Giuseppe L.
    Vasdev, Nikhil
    Ghose, Amit
    Noronha, Vanita
    Mitra, Swarupa
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
  • [24] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [25] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [26] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [27] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
  • [28] Response evaluation of 177Lu-PSMA-617 RLT using PSA, Chromogranin A, and LDH in 100 patients
    Rathke, H.
    Holland-Letz, T.
    Mier, W.
    Flechsig, P.
    Mavriopoulou, E.
    Roehrich, M.
    Kopka, K.
    Hohenfellner, M.
    Giesel, F.
    Haberkorn, U.
    Kratochwil, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S237 - S238
  • [29] 177Lu-PSMA-617 therapy in Chemotherapy Naive patients: A single center experience
    Kulkarni, Raksha
    Abdelrahman, Ahmed
    Novello, Matteo
    Cengiz, Turgut Bora
    Akinlusi, Rahman
    Bander, Ilda
    Patel, Vaibhav
    Wise, David
    Ghesani, Munir
    Ghesani, Nasrin
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [30] 177Lu-PSMA-617 Therapy in a Patient on Haemodialysis with End Stage Renal Failure
    MacFarlane, L.
    Eifer, M.
    Saghebi, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S248 - S248
12345